Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Celebrex In Acute Gouty Arthritis Study

ClinicalTrials.gov ID: NCT00549549

Public ClinicalTrials.gov record NCT00549549. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Multicenter, Active-Controlled Trial To Evaluate The Efficacy And Safety Of Celecoxib (Celebrex®) And Indomethacin In The Treatment Of Moderate To Severe Acute Gouty Arthritis

Study identification

NCT ID
NCT00549549
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
402 participants

Conditions and interventions

Interventions

  • Indomethacin Drug
  • Celecoxib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2008
Primary completion
Nov 30, 2009
Completion
Nov 30, 2009
Last update posted
Feb 20, 2021

2008 – 2009

United States locations

U.S. sites
43
U.S. states
21
U.S. cities
40
Facility City State ZIP Site status
Pfizer Investigational Site Glendale Arizona 85304
Pfizer Investigational Site Mesa Arizona 85202
Pfizer Investigational Site Paradise Valley Arizona 85253
Pfizer Investigational Site Peoria Arizona 85381
Pfizer Investigational Site Roseville California 95661
Pfizer Investigational Site San Diego California 92103-6204
Pfizer Investigational Site San Luis Obispo California 93405
Pfizer Investigational Site Longmont Colorado 80501
Pfizer Investigational Site Northglenn Colorado 80234
Pfizer Investigational Site DeLand Florida 32720
Pfizer Investigational Site Gainesville Florida 32607
Pfizer Investigational Site Tampa Florida 33606
Pfizer Investigational Site Atlanta Georgia 30342
Pfizer Investigational Site Dunwoody Georgia 30338
Pfizer Investigational Site Rockford Illinois 61107
Pfizer Investigational Site Lexington Kentucky 40504
Pfizer Investigational Site Mount Sterling Kentucky 40353
Pfizer Investigational Site Shreveport Louisiana 71105-5634
Pfizer Investigational Site Shreveport Louisiana 71106
Pfizer Investigational Site Wheaton Maryland 20902
Pfizer Investigational Site Lansing Michigan 48910-8595
Pfizer Investigational Site Chaska Minnesota 55318
Pfizer Investigational Site Columbia Missouri 65203
Pfizer Investigational Site Columbus Missouri 65212
Pfizer Investigational Site St Louis Missouri 63141
Pfizer Investigational Site Omaha Nebraska 68134
Pfizer Investigational Site Mineola New York 11501
Pfizer Investigational Site Statesville North Carolina 28625
Pfizer Investigational Site Lyndhurst Ohio 44124
Pfizer Investigational Site Willoughby Hills Ohio 44094
Pfizer Investigational Site Duncansville Pennsylvania 16635
Pfizer Investigational Site Havertown Pennsylvania 19083
Pfizer Investigational Site Nashville Tennessee 37203
Pfizer Investigational Site New Tazewell Tennessee 37825
Pfizer Investigational Site Beaumont Texas 77701
Pfizer Investigational Site Beaumont Texas 77706
Pfizer Investigational Site Bryan Texas 77802
Pfizer Investigational Site Dallas Texas 75235
Pfizer Investigational Site San Antonio Texas 78217
Pfizer Investigational Site San Antonio Texas 78224
Pfizer Investigational Site Tyler Texas 75701
Pfizer Investigational Site Richmond Virginia 23294
Pfizer Investigational Site Milwaukee Wisconsin 53295

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00549549, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 20, 2021 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00549549 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →